Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics

Asthma is characterized by chronic airway inflammation resulting from overproduction of pro-inflammatory mediators, such as leukotrienes (LT). The authors questioned the biosynthetic capacity of asthmatic patients for lipoxins (LX) and 15-epimer lipoxins (15-epi-LX), endogenous regulators of inflammatory responses that inhibit pro-inflammatory events. Levels of LXA4, 15-epi-LXA4 and LTC4 were determined in 14 clinically characterized aspirin-intolerant asthmatics (AIA), 11 aspirin-tolerant asthmatics (ATA) and eight healthy volunteers using a stimulated whole blood protocol. Both LXA4 and 15-epi-LXA4 were generated in whole blood activated by the divalent cation ionophore, A23187. Higher levels of LXA4 were produced in ATA than either AIA or healthy volunteers. Exposure of AIA whole blood to interleukin-3 prior to A23187 did not elevate their reduced capacity to generate LXA4. Generation of a bronchoconstrictor, LTC4, was similar in both AIA and ATA. Consequently, the ratio of LXA4:LTC4 quantitatively favoured the bronchoconstrictor for AIA and differed from both ATA and healthy subjects. In addition, the capacity for 15-epi-LXA4 generation was also diminished in AIA, since whole blood stimulated in the presence of aspirin gave increased levels only in samples from ATA. The present results indicate that asthmatics possess the capacity to generate both lipoxins and 15-epimer-lipoxins, but aspirin-intolerant asthmatics display a lower biosynthetic capacity than aspirin-tolerant asthmatics for these potentially protective lipid mediators. This previously unappreciated, diminished capacity for lipoxin formation by aspirin-intolerant asthmatic patients may contribute to their more severe clinical phenotype, and represents a novel paradigm for the development of chronic inflammatory disorders.

This article has been cited by other articles:

				F Gaber, K Daham, A Higashi, N Higashi, A Gulich, I Delin, A James, M Skedinger, P Gyllfors, M Nord, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma Thorax, December 1, 2008; 63(12): 1076 - 1082. [Abstract] [Full Text] [PDF]

				A. Planaguma, S. Kazani, G. Marigowda, O. Haworth, T. J. Mariani, E. Israel, E. R. Bleecker, D. Curran-Everett, S. C. Erzurum, W. J. Calhoun, et al. Airway Lipoxin A4 Generation and Lipoxin A4 Receptor Expression Are Decreased in Severe Asthma Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 574 - 582. [Abstract] [Full Text] [PDF]

				B. D. Levy, N. W. Lukacs, A. A. Berlin, B. Schmidt, W. J. Guilford, C. N. Serhan, and J. F. Parkinson Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism FASEB J, December 1, 2007; 21(14): 3877 - 3884. [Abstract] [Full Text] [PDF]

				O. Haworth and B. D. Levy Endogenous lipid mediators in the resolution of airway inflammation Eur. Respir. J., November 1, 2007; 30(5): 980 - 992. [Abstract] [Full Text] [PDF]

				C. Bonnans and B. D. Levy Lipid Mediators as Agonists for the Resolution of Acute Lung Inflammation and Injury Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 201 - 205. [Abstract] [Full Text] [PDF]

				B. D. Levy, P. Kohli, K. Gotlinger, O. Haworth, S. Hong, S. Kazani, E. Israel, K. J. Haley, and C. N. Serhan Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness J. Immunol., January 1, 2007; 178(1): 496 - 502. [Abstract] [Full Text] [PDF]

				M. I. Kidon, L. W. Kang, C. W. Chin, L. S. Hoon, Y. See, A. Goh, J. T. P. Lin, and O. M. Chay Early Presentation With Angioedema and Urticaria in Cross-reactive Hypersensitivity to Nonsteroidal Antiinflammatory Drugs Among Young, Asian, Atopic Children Pediatrics, November 1, 2005; 116(5): e675 - e680. [Abstract] [Full Text] [PDF]

				B. D. Levy, C. Bonnans, E. S. Silverman, L. J. Palmer, G. Marigowda, E. Israel, and for the Severe Asthma Research Program, National H Diminished Lipoxin Biosynthesis in Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 824 - 830. [Abstract] [Full Text] [PDF]

				N. Chiang, E. A. Bermudez, P. M. Ridker, S. Hurwitz, and C. N. Serhan Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial PNAS, October 19, 2004; 101(42): 15178 - 15183. [Abstract] [Full Text] [PDF]

				B. McMahon and C. Godson Lipoxins: endogenous regulators of inflammation Am J Physiol Renal Physiol, February 1, 2004; 286(2): F189 - F201. [Abstract] [Full Text] [PDF]

				C. N. Serhan, A. Jain, S. Marleau, C. Clish, A. Kantarci, B. Behbehani, S. P. Colgan, G. L. Stahl, A. Merched, N. A. Petasis, et al. Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators J. Immunol., December 15, 2003; 171(12): 6856 - 6865. [Abstract] [Full Text] [PDF]

				P. Boutet, F. Bureau, G. Degand, and P. Lekeux Imbalance Between Lipoxin A4 and Leukotriene B4 in Chronic Mastitis-Affected Cows J Dairy Sci, November 1, 2003; 86(11): 3430 - 3439. [Abstract] [Full Text] [PDF]

				A. Kantarci and T. E. Van Dyke LIPOXINS IN CHRONIC INFLAMMATION Critical Reviews in Oral Biology & Medicine, January 1, 2003; 14(1): 4 - 12. [Abstract] [Full Text] [PDF]

				A. J. Schottelius, C. Giesen, K. Asadullah, I. M. Fierro, S. P. Colgan, J. Bauman, W. Guilford, H. D. Perez, and J. F. Parkinson An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile J. Immunol., December 15, 2002; 169(12): 7063 - 7070. [Abstract] [Full Text] [PDF]

				C. N. Serhan and P. R. Devchand Novel Antiinflammatory Targets for Asthma . A Role for PPARgamma ? Am. J. Respir. Cell Mol. Biol., June 1, 2001; 24(6): 658 - 661. [Full Text] [PDF]